Capstan Medical Raises $31.4M and Leverages Robotics to Bring Minimally Invasive
With $31.4 million in new funding, the company will bring the benefits of robotics to one of the few remaining untouched areas of medicine, structural heart
More ›Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by
Boundless Bio announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital. Boundless Bio will use the financing to advance BBI-355, the first ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.
More ›Moon Surgical Raises Additional $55.4 Million in New Funding with Multiple Miles
Moon Surgical Raises Additional $55.4 Million in New Funding with Leading Investors Sofinnova Partners and NVIDIA, and Appoints Fred Moll as Board Chair
More ›Moon Surgical Closes a $31.3 Million Series A Round led by GT Healthcare to Acce
Moon Surgical, a pioneer in collaborative robotics, today announced that it has secured $31.3 million in Series A funding. The financing round was led by GT Healthcare Capital & Partners, with participation by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Cathay Health, and existing investor, Sofinnova Partners.
More ›【Portfolio News】Immunocore Holdings announces landmark FDA approval of TCR thera
GT portfolio company Immunocore Holdings plc (Nasdaq: IMCR) announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), the most common primary cancer within the eye in adults.
More ›